Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Address: NATCO HOUSERoad No.2, Banjara HillsHyderabad-500 033,India
Tel: +91-40-2354 7532
Web: http://www.natcopharma.co.in/
NATCO Pharma Limited is an Indian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
Background
Beginning:- NATCO PHARMA was promoted by Mr. V.C. Nannapaneni in the year 1981 as a Private Limited Company to be in the business of Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances and Finished Dosage forms for Indian and International markets. NATCO PHARMA began operations in 1984 in Andhra Pradesh, India.
First Success:- In the first year of its operations it achieved a sales figure of Rs. 0.5 million. The company’s first product was Cardicap, which is an Anti-Anginal drug. Since then the company has introduced many dosage forms into the market. By 1985 it had dosage forms in Cardiovascular, Anti-cold, Anti-Asthmatic and Antibiotic segments. NATCO has the credit of having pioneered Time Release Technology in India.
The Journey:- NATCO PHARMA was ranked 82nd in sales among Indian Pharmaceutical companies in 1994. NATCO also has the credit of being one of the largest contract manufacturers in India. Some of the well-known companies like Ranbaxy, Dr. Reddy’s Laboratories, John Wyeth etc. get their products manufactured by NATCO. NATCO PHARMA grew in size when three companies merged with it.
NATCO Parenterals Limited
Dr. Karanth Pharma Labs Private Limited
NATCO Laboratories Limited
Today:- NATCO PHARMA LIMITED, which began its operations as a single unit with 20 employees, today has four manufacturing facilities and employs around 1500 people. It has an on-line data for Analysis and decision making. Consistently ranked among the fastest growing pharmaceutical companies in the country, Natco is utilizing its collective experience to kick start its future plans as a global company. Respected for Quality, Performance, Care, Responsibility and for creation and maximization of wealth for its shareholders NATCO Pharma Limited, the post-merger organization represents a strategic stage in NATCO’s constant evolution as the Complete Pharma Company.
TIGI
URINAT
PRIMANAT
AMINAT
VORIZOL
NATCLOVIR
NATFLU
X-VIR
BUNIDE-CR
OMENAT
NATZOLD
BANDRONE 150
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He…
Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse, Our greatest ability…
Dr Santosh Indraksha serves as Deputy Drugs Controller (India) for the Central Drugs Standard Control Organisation (CDSCO) under the Indian Ministry of Health and Family Welfare. As a representative of…
Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened…
Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights…
Drawing on a unique background in both medicine and law, Dr Milind Antani today leads the pharma and healthcare practice at Nishith Desai Associates, covering everything from regulatory work to…
J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management…
Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has…
Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal…
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
See our Cookie Privacy Policy Here
